CORT Valuation

Corcept Therapeutics Inc

Add to Watchlist

Advanced Chart

72.770

+1.290(+1.800%)

Overview
Forecast
Valuation

CORT Relative Valuation

CORT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CORT is overvalued; if below, it's undervalued.

Historical Valuation

Corcept Therapeutics Inc (CORT) is now in the Overvalued zone, suggesting that its current forward PE ratio of 43.01 is considered Overvalued compared with the five-year average of 26.84. The fair price of Corcept Therapeutics Inc (CORT) is between 44.45 to 61.21 according to relative valuation methord. Compared to the current price of 72.77 USD , Corcept Therapeutics Inc is Overvalued By 18.88%.

Relative Value

Fair Zone

44.45-61.21

Current Price：72.77

18.88%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

11.28

P/B

Median3y

6.41

Median5y

5.83

2.58

FCF Yield

Median3y

4.56

Median5y

5.47

Competitors Valuation Multiple

The average P/S ratio for CORT's competitors is 24.84, providing a benchmark for relative valuation. Corcept Therapeutics Inc Corp (CORT) exhibits a P/S ratio of 8.37, which is -66.30% above the industry average. Given its robust revenue growth of 34.33%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CORT.O

Corcept Therapeutics Inc

8.37

Average P/S: 24.84

34.33%